Abstract
In the past decades considerable evidence has emerged that certain so called neuroactive steroids not only act as transcription factors in the regulation of gene expression but may also alter neuronal excitability through interaction with specific neurotransmitter receptors such as γ-aminobutyric acid type A (GABAA), N-methyl-D-aspartate (NMDA) and glutamate receptors. There is growing evidence that neuroactive steroids play an important role as endogenous modulators of neuronal function and behavioural processes and that alterations of endogenous neuroactive steroid concentrations may contribute to the pathophysiology of affective disorders. In view of their positive allosteric potential at GABAA-receptors, especially 3α-reduced neuroactive steroids have been suggested to play a major role in the pathophysiology of anxiety disorders. In panic disorder patients a dysequilibrium of neuroactive steroid composition has been observed, which may represent counterregulatory mechanisms against the occurrence of spontaneous panic attacks. Therefore, attenuation of neuroactive steroid concentrations either by synthetic derivates of neuroactive steroids or by modulation of endogenous neurosteroid synthesis might constitute a promising novel strategy for the treatment of anxiety disorders. In conclusion, neuroactive steroids are important endogenous modulators of depression and anxiety and may provide a basis for development of novel therapeutic agents in the treatment of affective disorders.
Keywords: Anxiety disorders, neurosteroids, GABAA-receptor, ligand-gated ion channel, antidepressants, CCK-4, panic disorder
Current Pharmaceutical Design
Title: Neuroactive Steroids as Endogenous Modulators of Anxiety
Volume: 14 Issue: 33
Author(s): Daniela Eser, Thomas C. Baghai, Cornelius Schule, Caroline Nothdurfter and Rainer Rupprecht
Affiliation:
Keywords: Anxiety disorders, neurosteroids, GABAA-receptor, ligand-gated ion channel, antidepressants, CCK-4, panic disorder
Abstract: In the past decades considerable evidence has emerged that certain so called neuroactive steroids not only act as transcription factors in the regulation of gene expression but may also alter neuronal excitability through interaction with specific neurotransmitter receptors such as γ-aminobutyric acid type A (GABAA), N-methyl-D-aspartate (NMDA) and glutamate receptors. There is growing evidence that neuroactive steroids play an important role as endogenous modulators of neuronal function and behavioural processes and that alterations of endogenous neuroactive steroid concentrations may contribute to the pathophysiology of affective disorders. In view of their positive allosteric potential at GABAA-receptors, especially 3α-reduced neuroactive steroids have been suggested to play a major role in the pathophysiology of anxiety disorders. In panic disorder patients a dysequilibrium of neuroactive steroid composition has been observed, which may represent counterregulatory mechanisms against the occurrence of spontaneous panic attacks. Therefore, attenuation of neuroactive steroid concentrations either by synthetic derivates of neuroactive steroids or by modulation of endogenous neurosteroid synthesis might constitute a promising novel strategy for the treatment of anxiety disorders. In conclusion, neuroactive steroids are important endogenous modulators of depression and anxiety and may provide a basis for development of novel therapeutic agents in the treatment of affective disorders.
Export Options
About this article
Cite this article as:
Eser Daniela, Baghai C. Thomas, Schule Cornelius, Nothdurfter Caroline and Rupprecht Rainer, Neuroactive Steroids as Endogenous Modulators of Anxiety, Current Pharmaceutical Design 2008; 14 (33) . https://dx.doi.org/10.2174/138161208786848838
DOI https://dx.doi.org/10.2174/138161208786848838 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives
Current Pharmaceutical Design Tuning and Fine-Tuning of Synapses with Adenosine
Current Neuropharmacology Biologically Active Selenophenes and Benzo[b]selenophenes
Current Organic Synthesis Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Combined Therapies for Lysosomal Storage Diseases
Current Molecular Medicine Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Allele Frequency Distributions of the Drug Metabolizer Genes <i>CYP2C9*2</i>, <i>CYP2C9*3</i>, and <i>CYP2C19*17</i> in the Buginese Population of Indonesia
Current Pharmacogenomics and Personalized Medicine Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds Neuropharmacology of Vestibular System Disorders
Current Neuropharmacology Early Detection of Epileptic Seizures in Sparse Domains
Neuroscience and Biomedical Engineering (Discontinued) Anticonvulsant, Anxiolytic and Antidepressant Properties of the β-caryophyllene in Swiss Mice: Involvement of Benzodiazepine-GABAAergic, Serotonergic and Nitrergic Systems
Current Molecular Pharmacology Convection Enhanced Delivery of Macromolecules for Brain Tumors
Current Drug Discovery Technologies Homocysteine and Cerebral Stroke in Developing Countries
Current Medicinal Chemistry Zebrafish as a Platform for Studies on Seizures and Epilepsy
Current Psychopharmacology Valproate Induced Acute Pancreatitis - A Unique Case Report
Current Drug Safety Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Amygdalar Atrophy in Early Alzheimer’s Disease
Current Alzheimer Research The Role of Newer Antiglutamatergic Agents as Mood-Stabilizers in Bipolar Disorder
Current Drug Targets Growth Factors and Astrocytes Metabolism: Possible Roles for Platelet Derived Growth Factor
Medicinal Chemistry